Monitor the November 12 special meeting vote outcome and any subsequent 8-K filing. If the reverse split is approved and implemented, watch for the specific ratio selected and any follow-on equity offering. The activist 3i, LP's continued accumulation and potential proxy fight escalation are key catalysts.
Price Chart
Executive Summary
Valion Bio is holding a special meeting on November 12, 2026, to seek stockholder approval for a reverse stock split (1-for-2 to 1-for-12) to maintain Nasdaq listing compliance and to increase the 2021 Equity Incentive Plan by 272,000 shares. The filing comes amid recent activist stake-building by 3i, LP, which holds 9.9% of common stock and has been purchasing shares at prices between $0.16 and $2.92 over the past 60 days, signaling potential proxy fight pressure. The reverse split authorization and equity plan increase are defensive measures that could dilute existing holders and provide management with anti-takeover flexibility.
Key Facts
- Special meeting on November 12, 2026, to vote on reverse stock split (1-for-2 to 1-for-12) and increase equity plan by 272,000 shares.
- 2,155,637 shares of common stock outstanding as of October 15, 2026 record date; only ~95 stockholders of record.
- Activist 3i, LP holds 9.9% beneficial ownership (132,671 shares) and has been actively purchasing shares in September 2026 at prices from $0.16 to $2.92.
- Reverse split authorized for up to 12 months; Board may abandon it at any time.
- Equity plan increase would bring total authorized shares to 400,783; pro-forma partially diluted overhang of 4.94%.
- No executive compensation details, shareholder proposals, or related party transactions disclosed in this filing.
- Board unanimously recommends 'FOR' all three proposals.
Financial Impact
Reverse split would not change authorized shares (200M) but would effectively increase available unissued shares proportionally, enabling future dilution. Equity plan increase adds 272,000 shares (4.94% pro-forma partially diluted overhang).
Risk Factors
- Reverse split may not boost stock price sustainably; post-split price could decline back to pre-split levels.
- Equity plan increase dilutes existing shareholders by 4.94% on a pro-forma basis.
- Activist 3i, LP may push for board changes or strategic alternatives, creating uncertainty.
- Nasdaq delisting risk remains if bid price falls below $1.00 even after reverse split.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001683168-26-007932 |
| Document: 0001683168-26-007932-index-headers.html | 0001683168-26-007932 |
| Document: 0001683168-26-007932-index.html | 0001683168-26-007932 |
| Document: 0001683168-26-007932.txt | 0001683168-26-007932 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.8139 (+9.06%) |
Oct 26, 2026 1d ago | 8-K | $1.15 | awaiting T+20 | — | $0.8139 (−28.97%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8139 (−14.86%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8139 (+27.33%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8139 (+27.33%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8139 (+29.84%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8139 (+29.84%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8139 (−33.83%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8139 (−43.87%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8139 (+63.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers